Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Vitrolife makes the lab supplies and equipment that fertility clinics need to grow embryos for IVF.
Vitrolife is a Swedish medical company that sells the behind-the-scenes gear for IVF. When a couple goes to a fertility clinic, the lab there needs a whole set of special liquids, dishes, and machines to fertilize an egg and keep the resulting embryo alive for a few days. Vitrolife makes much of that kit: nutrient solutions that mimic the fluid inside a human body, plastic dishes and needles for handling eggs and sperm, and incubators and freezers that keep embryos at the right temperature and let clinics store them for later.
The business is best understood by the problem it solves. An embryo outside the body is fragile, and the liquid around it has to be just right or it stops growing. Vitrolife sells those liquids and the single-use plastic that goes with them, which clinics buy again and again for every patient cycle. It also sells the bigger machines — incubators that watch embryos grow and freezers that preserve them at very low temperatures. Add it up and you get a company with annual revenue of around 3.6 billion Swedish kronor, holding a strong position in a niche where the customer cares enormously about getting the details right. Vitrolife has two parts. The main one sells consumables and equipment to clinics. The other, smaller part sells genomics tools used in research, mainly for looking at DNA. Clinics tend to stick with a supplier once their lab is set up and their staff are trained, so switching is a hassle. That stickiness is the core of the business: once a lab standardizes on Vitrolife's fluids for its incubators and processes, changing suppliers means retraining people and revalidating results, which few labs want to do.
The company has been a serial acquirer, buying up smaller players in fertility and genomics to expand what it can offer clinics and to grow outside its home region. That strategy has a cost: debt and goodwill pile up, and integrating new businesses takes time. More recently, the fertility market has cooled somewhat, and growth has come under pressure. The deeper vulnerability is that in many rich countries, IVF demand depends on how many people are trying to have children and whether governments or insurers help pay for it. When birth rates fall and budgets tighten, clinics do fewer cycles, and Vitrolife sells less. It is a high-quality niche business, but it is tied to a market shaped by demographics and policy, not just by how good its products are.
Saved answer · last researched 26 Oct 2026